• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伊马替尼诱发的费城染色体阳性慢性髓性白血病甲状腺炎

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.

作者信息

Singh Surjit, Sharma Pramod Kumar

机构信息

Department of Pharmacology, AIIMS, Jodhpur, Rajasthan, India.

出版信息

Indian J Pharmacol. 2016 Jul-Aug;48(4):458-459. doi: 10.4103/0253-7613.186214.

DOI:10.4103/0253-7613.186214
PMID:27756963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4980940/
Abstract

Here, we present a case of chronic myeloid leukemia for which imatinib therapy was initated. Triiodothyronine (T3), thyroxine (T4), and thyroid-stimulating hormone was normal, and thyroid microsomal autoantibodies (TMA) were positive and patient was diagnosed as thyroiditis treated with corticosteroids for 1½ months which lead to resolution.

摘要

在此，我们报告一例开始接受伊马替尼治疗的慢性髓性白血病病例。三碘甲状腺原氨酸（T3）、甲状腺素（T4）及促甲状腺激素均正常，甲状腺微粒体自身抗体（TMA）呈阳性，患者被诊断为甲状腺炎，接受了1个半月的皮质类固醇治疗，随后病情缓解。

相似文献

1
Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.伊马替尼诱发的费城染色体阳性慢性髓性白血病甲状腺炎
Indian J Pharmacol. 2016 Jul-Aug;48(4):458-459. doi: 10.4103/0253-7613.186214.
2
Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.一名慢性髓性白血病分子缓解期患者在伊马替尼治疗期间出现del(20q)，停用伊马替尼后其减少。
Leuk Lymphoma. 2016;57(1):201-2. doi: 10.3109/10428194.2015.1037763. Epub 2015 May 12.
3
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.有多少慢性髓系白血病患者能够从诊断进展至深度分子反应并长期停用伊马替尼？一项真实病例经验。
Br J Haematol. 2017 Feb;176(4):669-671. doi: 10.1111/bjh.13983. Epub 2016 Feb 23.
4
Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.达沙替尼成功用于慢性髓性白血病伊马替尼诱导的暴发性肝衰竭肝移植术后
J Clin Oncol. 2016 Apr 10;34(11):e97-8. doi: 10.1200/JCO.2013.50.1320. Epub 2014 Sep 29.
5
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.伊马替尼——2015年用于慢性髓性白血病一线治疗的新型酪氨酸激酶抑制剂。
JAMA Oncol. 2015 May;1(2):143-4. doi: 10.1001/jamaoncol.2015.50.
6
miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.miR-505-5p和miR-193b-3p：慢性髓性白血病患者伊马替尼反应的潜在生物标志物。
Leuk Lymphoma. 2017 Aug;58(8):1981-1984. doi: 10.1080/10428194.2016.1272681. Epub 2017 Jan 16.
7
Newly diagnosed breast cancer in a patient receiving imatinib mesylate.一名正在接受甲磺酸伊马替尼治疗的患者新诊断出乳腺癌。
J Cancer Res Ther. 2014 Oct-Dec;10(4):1107-8. doi: 10.4103/0973-1482.146095.
8
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.伊马替尼一线治疗慢性髓性白血病患者的长期疗效。
Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.
9
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.甲磺酸伊马替尼用于慢性髓性白血病：一线治疗及长期疗效
Expert Rev Anticancer Ther. 2016;16(3):273-8. doi: 10.1586/14737140.2016.1151356.
10
Imatinib mesylate-induced pseudoporphyria in a patient with chronic myeloid leukemia.甲磺酸伊马替尼致一名慢性髓性白血病患者发生假性卟啉症。
Indian J Dermatol Venereol Leprol. 2016 Nov-Dec;82(6):727-729. doi: 10.4103/0378-6323.186477.

引用本文的文献

1
Impact of Tyrosine Kinase Inhibitors on Thyroid Function in Chronic Myeloid Leukemia: A Systematic Review.酪氨酸激酶抑制剂对慢性髓性白血病甲状腺功能的影响：一项系统评价
Cureus. 2025 Jun 1;17(6):e85196. doi: 10.7759/cureus.85196. eCollection 2025 Jun.
2
The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review.伊马替尼治疗慢性髓性白血病相关肝毒性和甲状腺毒性的发生率：系统评价。
Int J Clin Pharm. 2024 Apr;46(2):368-381. doi: 10.1007/s11096-023-01671-0. Epub 2023 Dec 26.

本文引用的文献

1
Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.酪氨酸激酶抑制剂引起的甲状腺功能障碍：发病率、病理生理学、临床相关性和治疗的综述。
Biomed Res Int. 2013;2013:725410. doi: 10.1155/2013/725410. Epub 2013 Oct 27.
2
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.尼洛替尼与伊马替尼用于治疗新诊断的慢性髓性白血病。
N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.
3
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.舒尼替尼治疗肾细胞癌期间出现的甲状腺毒症。
Clin Endocrinol (Oxf). 2008 Oct;69(4):669-72. doi: 10.1111/j.1365-2265.2008.03253.x. Epub 2008 Apr 3.
4
A method for estimating the probability of adverse drug reactions.一种估算药物不良反应概率的方法。
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
5
Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.慢性粒细胞白血病中与易位断点相邻的c-ab1癌基因的定位。
Nature. 1983;306(5940):239-42. doi: 10.1038/306239a0.